Key facts
- This page summarizes John Simard's Form 4 filing for XBiotech Inc. (XBIT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Feb 2025, 16:53.
John Simard - 31 Jan 2025 Form 4 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- XBIT
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$24,703,550,000,000
- SEC form
- 4
- Accepted by SEC
- 04 Feb 2025, 16:53:27 UTC
- Prior SEC filing
- 05 Jan 2024
- Next SEC filing
- 19 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- John Simard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Simard filed Form 4 for XBiotech Inc. (XBIT) on 04 Feb 2025.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: -$24,703,550,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001639078
Primary reporting owner
SIMARD JOHN
- Relationship
- Chief Executive Officer, Director, 10%+ Owner
- Address
- 5217 WINNEBAGO LANE, AUSTIN
- Signature
- John Simard
- Signature date
- 03 Feb 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XBIT
transaction
Derivative
Convertible Loan Agreement
Other
- Transaction value
- $24,703,550,000,000
- Shares
- -2,470,355
- Change %
- -74%
- Price
- $10000000.00
- Shares after
- 870,381
- Date
- 31 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares or Preferred Shares
- Underlying amount
- 2,470,335
- Exercise price
- $4.05
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On January 31, 2025, the Convertible Loan Agreement (the "Loan") dated as of January 3, 2024 between XBiotech Inc. and John Simard, the Company's Founder, President, Chief Executive Officer, and Chairman, was terminated upon full repayment of the Loan by the Company. As a result, all conversion rights to XBiotech stock associated with the Loan were extinguished.